Monday, July 9, 2012

Healthcare Stocks: Questcor Pharmaceuticals Jumps 15% (QCOR, NSPH, AGP, AMPE, CELG)

Questcor Pharmaceuticals Inc (NASDAQ:QCOR) soared 15.23% to $57.88. The Company’s preliminary June estimates for its shipped paid Acthar prescriptions show month-to-month increases as the company has worked to broaden physician awareness for its prescriptions though expansion of its sales force. The Company reported paid prescriptions treating Nephrotic Syndrome came in at 115 to 120 for June. Questcor Pharmaceuticals has completed the expansion of its nephrology sales force, increasing its representatives to 58 from 28. Total Acthar shipments reached 4710 vials for the second quarter ended in June.

The Company repurchased 3.7 million shares of its common stock during the second quarter, at an average price of $41.85.

Nanosphere Inc (NASDAQ:NSPH) among the gainers and the stock escalated 8.15% to $3.45. Roth Capital upgraded the rating on the stock from neutral to buy.
Recently, the U.S. Food and Drug Administration have granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test on the automated sample-to-result Verigene System.

AMERIGROUP Corporation (NYSE:AGP) is one of the top percentage gainers and soared 38.0% to $88.79. WellPoint Inc and AMERIGROUP Corporation have entered into a definitive agreement. WellPoint will acquire Amerigroup for $92.00 per share in cash by purchasing all the outstanding shares of Amerigroup. The transaction value is approximately $4.9 billion. After the acquisition, WellPoint with its affiliated Medicaid plans will serve more than four-and-a-half million beneficiaries of state sponsored health care programs.

Ampio Pharmaceuticals Inc (NASDAQ:AMPE) moved up 2.50% to $4.94. The Company announced the significant results from their further analysis of its Optina trial on DME. The primary endpoint was change from baseline to week twelve of treatment in retinal thickness as measured by Optical Coherence Tomography.

Celgene Corporation (NASDAQ:CELG) is up marginally 0.23%to $64.89. According to a source in contact with Celgene management, the Company is not buying Human Genome Sciences.

No comments:

Post a Comment

Privacy Policy | Legal Disclaimer